Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 24, 2013
SAN DIEGO, CA, September 24, 2013 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per share. The gross proceeds to Evoke Pharma from the init...
Sep 30, 2013
SAN DIEGO, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the closing of its previously announced initial public offering of common stock. The Company sold a total of 2,100,000 shares of its common stock, at an initial ...
Oct 3, 2013
SAN DIEGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 315,000 shares of its common stock, at a...
Nov 5, 2013
SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2013 on Wednesday, November 13, 2013, after the close of the market. Evoke will hold a co...
Nov 13, 2013
SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2013. Dave Gonyer, R.Ph., President and CEO, stated, "With the net proceeds of our initial...
Nov 26, 2013
SAN DIEGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its upcoming Phase 3 clinical trial of EVK-001. EVK-001 is ...
Dec 2, 2013
SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced today the appointment of Marilyn R. Carlson, D.M.D., M.D., RAC, as Chief Medical Officer and Wayne Alves, Ph.D., as Senior Director of Clinical Operations. These two exe...
Jan 7, 2014
SAN DIEGO, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer is scheduled to present at Biotech Showcase™ 2014, being held January 13-15, 2014 in San Francisc...
Jan 22, 2014
SAN DIEGO, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the ma...
Mar 4, 2014
SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26th Annual ROTH Conference, being held March 10-12, 2014 at the Rit...
Mar 10, 2014
SAN DIEGO, March 10, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market. Evoke will hold a conf...
Mar 25, 2014
SOLANA BEACH, Calif., March 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013. Dave Gonyer, R.Ph., President and CEO, stated, "2013 was an exc...
Apr 22, 2014
SOLANA BEACH, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its Phase 3 clinical trial investigating the use of EVK-001, a novel metoclopramide nasal spray for the relief of symptoms associate...
Apr 28, 2014
SOLANA BEACH, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation and delivery method of metoclopramide for diabetic fem...
May 6, 2014
SOLANA BEACH, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the First Quarter of 2014 on Tuesday, May 13, 2014, after the close of the market. Evoke will hold a...
Page:
...
Next Last
 
= add release to Briefcase